Published in Rheumatology (Oxford) on March 11, 2010
Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies. BMC Musculoskelet Disord (2014) 0.78
Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther (2016) 0.77
Spondyloarthritides: evolving therapies. Arthritis Res Ther (2010) 0.77
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord (2015) 0.77
Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag (2016) 0.75
Efficacy and safety of adalimumab in ankylosing spondylitis. Open Access Rheumatol (2014) 0.75
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol (2012) 0.75
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs R D (2017) 0.75
Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum (2006) 10.39
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med (2002) 7.05
Retroperitoneal fibrosis. Lancet (2006) 4.57
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med (2007) 3.81
2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis (2012) 3.47
Polymyalgia rheumatica and giant-cell arteritis. Lancet (2008) 3.40
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum (2005) 3.31
Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet (2011) 3.19
Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11
Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol (2011) 2.45
Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2004) 2.43
Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum (2005) 2.39
Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol (2007) 2.33
Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med (2007) 2.27
2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum (2012) 2.25
Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol (2009) 2.19
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol (2012) 2.18
The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09. Rheumatology (Oxford) (2013) 2.14
Autophagy in human health and disease. N Engl J Med (2013) 2.04
Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol (2008) 2.00
Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol (2003) 1.99
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis?. Ann Intern Med (2002) 1.86
Gout: why is this curable disease so seldom cured? Ann Rheum Dis (2012) 1.84
Early psoriatic arthritis: the clinical spectrum. J Rheumatol (2007) 1.79
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood (2010) 1.67
Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. Rheumatology (Oxford) (2009) 1.60
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
Inflammation as "common soil" of the multifactorial diseases. Autoimmun Rev (2010) 1.57
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol (2011) 1.51
Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology (Oxford) (2009) 1.49
The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev (2011) 1.47
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists? Arthritis Care Res (Hoboken) (2012) 1.46
Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) (2011) 1.45
An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun Rev (2011) 1.44
Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 1.43
Isolated aortitis versus giant cell arteritis: are they really two sides of the same coin? Clin Exp Rheumatol (2014) 1.43
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38
An unusual cause of dysphagia. J Rheumatol (2012) 1.38
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nat Genet (2013) 1.34
Retracted Drug-induced lupus erythematosus. Autoimmunity (2005) 1.31
Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum (2008) 1.30
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) (2013) 1.29
Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep (2013) 1.25
Ileal pouchitis-related arthritis. Semin Arthritis Rheum (2002) 1.23
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21
Enthesitis. Best Pract Res Clin Rheumatol (2006) 1.21
Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev (2008) 1.20
Patient-reported outcomes in polymyalgia rheumatica. J Rheumatol (2012) 1.20
The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev (2006) 1.19
Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol (2006) 1.19
Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum (2007) 1.18
Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum (2005) 1.18
Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther (2004) 1.18
Strong intra- and inter-continental differentiation revealed by Y chromosome SNPs M269, U106 and U152. Forensic Sci Int Genet (2010) 1.17
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis (2014) 1.17
Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol (2004) 1.17
Biopsy findings in primary angiitis of the central nervous system. Am J Surg Pathol (2009) 1.17
High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood (2003) 1.16
Resistant Behçet disease responsive to anakinra. Ann Intern Med (2008) 1.15
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum (2011) 1.15
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis (2012) 1.15